A Comparison of effect of Kantakaryadi Kwatha and Bhunimbadi Kwatha in Acidity

Phase 2/3

Not yet recruiting

• Conditions: Gastro-esophageal reflux disease without esophagitis,

• Registration Number: CTRI/2020/09/028034
• Lead Sponsor: Ayurved Mahavidyalaya Nashik

Brief Summary

In modern era amlapitta is a most remarkable problem in the society it is a very common disease mostly affecting the adult men and women in the Indian population As the treatment the use of antacids which has symptomatic relief only Antacids that contain aluminum hydroxide may cause[constipatio](https://www.rxlist.com/script/main/art.asp?articlekey=2829)[n](https://www.rxlist.com/script/main/art.asp?articlekey=2829)aluminum intoxication osteomalacia and hypophosphatemia  Kantakaryadi kwatha is a drug of choice for Amlapitta contain all the necessary ingredients that are useful to breakdown pathophysiology of Amlapitta by their rasa and virya properties   Kantakaryadi kwatha will be preparaed as per reference mentioned in ayurvedic text under supervision of experts in Dept. Of Rasashastra & Bhaishajyakalpana of Ayurved Seva Sangh College Nashik  and Bhunumbadi Kwatha is a drug of choice for parallel study It is prepared by a GMP certified Ayurvedic drug manufacturing company The clinical study to evaluate the efficacy of these drugs will be beneficial to the practitioners of Ayurveda throughtout the world so here study is designed to evaluate the efficacy of Kantakaryadi Kwatha internally twice a daily for 21 days and Bhunimbadi Kwatha internally twice a daily for 21 days in the management of Amlapitta

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2020-09-21
• Study Start: 2020-09-30

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Obesity induce hyperacidity Patients fulfilling the diagnostic criteria which are based on sign and symptoms of amlapitta.

Exclusion Criteria

Patient not willing for clinical trial Pregnant and lactating mothers Patients suffering from any other chronic systemic disorders stomach abnormality like hiatus hernia Connective tissue disorders such as scleroderma Taking other medicine like aspirin ibuprofen Non steroidal anti inflammatory drugs High blood pressure medicine Iron supplements tricyclic antidepressants Anti-anxiety drugs etc.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction of acid reflux	21 days

Secondary Outcome Measures

Name	Time	Method
Reduction of associate symptoms related to acidity	21 days

Trial Locations

Locations (1)

Arogyashala Rugnalaya; 🇮🇳 Nashik, MAHARASHTRA, India

Arogyashala Rugnalaya

🇮🇳Nashik, MAHARASHTRA, India

Dr Srajan Madhur Jain

Principal investigator

8770103338

srajan07jul@gmail.com